Association of Transcription Factor APRF and Protein Kinase Jak1 with the Interleukin-6 Signal Transducer gp130
Abstract
Interleukin-6 (IL-6), leukemia inhibitory factor, oncostatin M, interleukin-11, and ciliary neurotrophic factor bind to receptor complexes that share the signal transducer gp130. Upon binding, the ligands rapidly activate DNA binding of acute-phase response factor (APRF), a protein antigenically related to the p91 subunit of the interferon-stimulated gene factor-3α (ISGF-3α). These cytokines caused tyrosine phosphorylation of APRF and ISGF-3α p91. Protein kinases of the Jak family were also rapidly tyrosine phosphorylated, and both APRF and Jak1 associated with gp130. These data indicate that Jak family protein kinases may participate in IL-6 signaling and that APRF may be activated in a complex with gp130.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both IFNγ and IL-6 can activate JAK1 and JAK2, and subsequently STAT1 and STAT3.
“Both IFN␥ and IL-6 can activate JAK1 (4 -6) and JAK2 (7-10), and subsequently STAT1 (11,12) and STAT3 (6,13,14).”
From The Comparative Roles of Suppressor of Cytokine Signaling-1 and -3 in the Inhibition and Desensitization of Cytokine Signaling (2006) · cites this paper as [6]
Cites
Kessler, D. S., Veals, S. A., Fu, X. Y., & Levy, D. E. (1990) · Genes & Development · doi:10.1101/gad.4.10.1753 · Cited by 312 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · see citing works
Self-citationZhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · see citing works
Bôle-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. (1998) · Endocrine reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,973 · see citing works
“IL-6-activated transcription factor (552).”
Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3.Preprint
Niwa, H., Burdon, T., Chambers, I., & Smith, A. G. (1998) · Genes & Development · doi:10.1101/gad.12.13.2048 · Cited by 1,673 · see citing works
Gp130 and the interleukin-6 family of cytokines.
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,603 · see citing works
Self-citationInterleukin-6 family of cytokines and gp130.
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,362 · see citing works
Self-citationTranscriptional Regulation by Extracellular signals: Mechanisms and Specificity
Hill, C. S., & Treisman, R. (1995) · Cell · doi:10.1016/0092-8674(95)90403-4 · Cited by 1,263 · see citing works
Hirano, T., Ishihara, K., & Hibi, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203551 · Cited by 1,187 · see citing works
“…of gp130 or heterodimerization of gp130 with other gp130-related receptors (LIF receptor b, OSM receptor a, and CT-1 receptor a), which results in the activation of the gp130-associated Janus kinases (JAK1, JAK2, and TYK2) (Lutticken et al., 1994; Matsuda et al., 1994; Stahl et al., 1994).”
BackgroundRippon, H. J., & Bishop, A. E. (2004) · Cell Proliferation · doi:10.1111/j.1365-2184.2004.00298.x · Cited by 536 · see citing works
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway.
Bonni, A., Sun, Y., Nadal-Vicens, M., Bhatt, A. S., Frank, D., Rozovsky, I., Stahl, N., Yancopouloš, G., & Greenberg, M. (1997) · Science · doi:10.1126/science.278.5337.477 · Cited by 1,050 · see citing works
Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., & Kishimoto, T. (1994) · Cell · doi:10.1016/0092-8674(94)90235-6 · Cited by 1,019 · see citing works
Self-citationJaks and Stats in signaling by the cytokine receptor superfamily.
Ihle, J., & Kerr, I. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89000-9 · Cited by 953 · see citing works
Transcription factors: an overview.
Latchman, D. (1997) · International Journal of Biochemistry and Cell Biology · doi:10.1016/s1357-2725(97)00085-x · Cited by 938 · see citing works
Levy, D., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15650 · Cited by 925 · see citing works
“IL-6–type cytokines evoke a number of distinct responses in different cells, including induction of an acute-phase response in hepatoma cells, stimulation of proliferation in B lymphocytes, activation of terminal differentiation and growth arrest in monocytes (11), and maintenance of the pluripotency of embryonic stem…”
BackgroundInfluentialThe two faces of IL-6 on Th1/Th2 differentiation
Diehl, S. A., & Rincón, M. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00210-9 · Cited by 873 · see citing works
Interleukin 6 and its receptor: ten years later
Hirano, T. (1998) · International Reviews of Immunology · doi:10.3109/08830189809042997 · Cited by 788 · see citing works
Cytoplasmic signaling pathways that regulate cardiac hypertrophy.
Molkentin, J., & Dorn, G. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.391 · Cited by 760 · see citing works
Hillmer, E. J., Zhang, H., Li, H. S., & Watowich, S. S. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.05.001 · Cited by 740 · see citing works
Interleukin-6 Family CytokinesPreprint
Rose‐John, S. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 801 · see citing works
“During the 1990s, intracellular signaling induced by activated gp130 was recognized to be mainly mediated by JAKs constitutively associated with the cytoplasmic portion of gp130, which led to the recruitment and activation of signal transducers and activators of transcription (STATs), which on phosphorylation by JAKs…”
BackgroundInfluentialPerry, R. J., Camporez, J.-P. G., Kursawe, R., Titchenell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X.-M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.012 · Cited by 719 · see citing works
“…HGP was associated with a 50% reduction in hepatic acetyl CoA concentrations within 10 min of the start of the insulin infusion as well as a 60% suppression of whole-body glycerol and palmitate turnover at steady state with no changes in plasma lactate, glucagon, or liver glycogen concentrations (”
BackgroundMitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716 · see citing works
Cytokine signaling through nonreceptor protein tyrosine kinases.
Taniguchi, T. (1995) · Science · doi:10.1126/science.7716517 · Cited by 712 · see citing works
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N., & Fuller, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 684 · see citing works
Mui, A., Wakao, H., O'Farrell, A.-M., Harada, N., & Miyajima, A. (1995) · EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07100.x · Cited by 674 · see citing works
Signaling by the cytokine receptor superfamily: JAKs and STATs
Ihle, J. N., Witthuhn, B. A., Quelle, F. W., Yamamoto, K., Thierfelder, W. E., Kreider, B. L., & Silvennoinen, O. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90026-4 · Cited by 648 · see citing works
Signal Transducer and Activator of Transcription‐3, Inflammation, and Cancer
Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04911.x · Cited by 652 · see citing works
Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., & Hirano, T. (1996) · Immunity · doi:10.1016/s1074-7613(00)80501-4 · Cited by 652 · see citing works
Löffler, D., Brocke-Heidrich, K., Pfeifer, G., Stocsits, C., Hackermüller, J., Kretzschmar, A. K., Burger, R., Gramatzki, M., Blumert, C., Bauer, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081133 · Cited by 637 · see citing works
Self-citationChung, J., Uchida, E., Grammer, T. C., & Blenis, J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6508 · Cited by 620 · see citing works
“Once these growth factor or cytokine receptors are occupied by their ligands, tyrosine residues in the cytoplasmic domain of the receptors become phosphorylated by cytokine receptor-associated JAK family tyrosine kinases (19, 32) or by the growth factor-activated receptor tyrosine kinases (16, 26, 34).”
BackgroundRequirement of serine phosphorylation for formation of STAT-promoter complexes.
Zhang, X.-K., Blenis, J., Li, H., Schindler, C., & Chen-Kiang, S. (1995) · Science · doi:10.1126/science.7701321 · Cited by 604 · see citing works
Self-citationJAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 711 · see citing works
Nakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., Kitaoka, T., Fukada, T., Hibi, M., & Hirano, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00734.x · Cited by 565 · see citing works
Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation?
Biffl, W., Moore, E. E., Moore, F., & Peterson, V. M. (1996) · Annals of Surgery · doi:10.1097/00000658-199611000-00009 · Cited by 558 · see citing works
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernández-Rocha, C., Duijvestein, M., Faubion, W. A., McGovern, D. P. B., Vermeire, S., Vetrano, S., & Casteele, N. V. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 646 · see citing works
Differential Effects of Interleukin-6 and -10 on Skeletal Muscle and Liver Insulin Action In Vivo
Kim, H.-J., Higashimori, T., Park, S.-Y., Choi, H., Dong, J., Kim, Y.-J., Noh, H.-L., Cho, Y.-R., Cline, G., Kim, Y.-B., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1060 · Cited by 534 · see citing works
Interleukin-6: Biology, signaling and strategies of blockade
Schaper, F., & Rose‐John, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.004 · Cited by 511 · see citing works
Janus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 504 · see citing works
“JAK2 is activated following erythropoietin stimulation of its receptor (Witthuhn et al., 1993) while JAK1 and JAK2 have been implicated in signaling by IL-3, GM-CSF and IL-5 (Silvennoinen et al., 1993a; Quelle et al., 1994; Lutticken et al., 1994).”
BackgroundFrequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2009) · Nature · doi:10.1038/nature07475 · Cited by 477 · see citing works
Stein, T., Morris, J. S., Davies, C. R., Weber-Hall, S., Duffy, M., Heath, V. J., Bell, A. K., Ferrier, R., Sandilands, G., & Gusterson, B. (2003) · Breast Cancer Research · doi:10.1186/bcr753 · Cited by 440 · see citing works
Physical activity and modulation of systemic low-level inflammation
Bruunsgaard, H. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0505247 · Cited by 429 · see citing works
“IL-6 binds to the IL-6sR and the complex associates with two gp130 molecules for the initiation of intracellular signaling [171].”
BackgroundKotenko, S. V., Krause, C. D., Izotova, L. S., Pollack, B. P., Wu, W., & Pestka, S. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.5894 · Cited by 382 · see citing works
“We showed that, if the IFN-γR2cytokines, IL-10 and IL-12 (Velazquez et al., 1992; Bacon et al., 1995; Barbieri et al., 1994; Lütticken et al., 1994; intracellular domain is replaced with the intracellular domains of other receptors, Hu-IFN-γR1, Hu-IFN-αR2c,Stahl et al., 1994; Finbloom and…”
BackgroundEssential role of STAT3 for embryonic stem cell pluripotency
Raz, R., Lee, C., Cannizzaro, L. A., D’Eustachio, P., & Levy, D. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2846 · Cited by 399 · see citing works
Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D., Martin, T., Hirota, H., Taga, T., Kishimoto, T., et al. (1995) · Journal of Experimental Medicine · doi:10.1084/jem.182.5.1461 · Cited by 415 · see citing works
“The JAK family of protein kinases (JAK1, JAK2, and TYK2) and the latent cytoplasmic transcription factor A P R F / S T A T 3 participate in IL-6 signaling (40, 50, 51).”
Self-citationThe chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway
Vila-Coro, A., Rodríguez-Frade, J., de Ana, A. M., Moreno-Ortíz, C., Martínez-A, C., & Mellado, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.13.1699 · Cited by 412 · see citing works
Multiple Routes to Astrocytic Differentiation in the CNS
Rajan, P., & Mckay, R. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-10-03620.1998 · Cited by 409 · see citing works
“Signaling is initiated by members of the JAK family of tyrosine kinases, specifically Jak1, Jak2, and Tyk2 (Lutticken et al., 1994; Stahl et al., 1994).”
BackgroundSignaling mechanisms through gp130: A model of the cytokine system
Hirano, T., Nakajima, K., & Hibi, M. (1997) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(98)80005-1 · Cited by 370 · see citing works
Dechiara, T., Vejsada, R., Poueymirou, W., Acheson, A., Suri, C., Conover, J., Friedman, B., Mcclain, J., Pan, L., Stahl, N., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90172-8 · Cited by 395 · see citing works
Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C., & Schaper, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12848 · Cited by 388 · see citing works
Self-citationInterleukin‐6: Structure‐function relationships
Simpson, R. J., Hammacher, A., Smith, D. K., Matthews, J., & Ward, L. D. (1997) · Protein Science · doi:10.1002/pro.5560060501 · Cited by 388 · see citing works
Ueda, T., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108255200 · Cited by 381 · see citing works
Bode, J. G., Albrecht, U., Häussinger, D., Heinrich, P. C., & Schaper, F. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.008 · Cited by 379 · see citing works
Self-citationRahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377 · see citing works
“IL-6 activates Stat3 through the activation of gp130 that is associated with Jak1, Jak2 or Tyk2 (Lutticken et al., 1994; Stahl et al., 1994).”
BackgroundReich, N. C., & Liu, L. (2006) · Nature Reviews Immunology · doi:10.1038/nri1885 · Cited by 376 · see citing works
“Nuclear STAT3 independent of phosphorylation STAT3 was first identified as a DNA-binding factor that is activated by IL-6 to regulate gene expression in the acute-phase inflammatory respons”
BackgroundPennica, D., Shaw, K., Swanson, T. A., Moore, M. W., Shelton, D., Zioncheck, K., Rosenthal, A., Taga, T., Paoni, N., & Wood, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10915 · Cited by 368 · see citing works
Self-citationHistorical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360 · see citing works
Self-citationNiemand, C., Nimmesgern, A., Haan, S., Fischer, P., Schaper, F., Rossaint, R., Heinrich, P. C., & Müller-Newen, G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3263 · Cited by 357 · see citing works
Self-citationGerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P., & Graeve, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12991 · Cited by 351 · see citing works
Self-citationKern, L., Mittenbühler, M., Vesting, A., Ostermann, A., Wunderlich, C., & Wunderlich, F. (2018) · Cancers · doi:10.3390/cancers11010024 · Cited by 331 · see citing works
O'Brien, C. A., Gubrij, I., Lin, S.-C., Saylors, R., & Manolagas, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19301 · Cited by 326 · see citing works
Regulation of STAT‐dependent pathways by growth factors and cytokines
Leaman, D. W., Leung, S., Li, X.-X., & Stark, G. R. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.14.9002549 · Cited by 318 · see citing works
“For example, JAK1, JAK2, and Tyk2 can all be phosphorylated in response to IL-6, depending on the cell type used (17, 18).”
Pellegrini, S., & Dusanter‐Fourt, I. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00615.x · Cited by 281 · see citing works
Self-citationDual Oncostatin M (OSM) Receptors
Mosley, B., Imus, C. D., Friend, D., Boiani, N., Thoma, B., Park, L., & Cosman, D. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32635 · Cited by 307 · see citing works
Role of STAT2 in the alpha interferon signaling pathway
Leung, S., Qureshi, S. A., Kerr, I. M., Darnell, J. E., & Stark, G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1312 · Cited by 307 · see citing works
“The same two factors are also activated in response to IL-6 (23).”
BackgroundThe Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.
Heim, M. (1999) · Journal of Receptor and Signal Transduction Research · doi:10.3109/10799899909036638 · Cited by 300 · see citing works
Molden, J., Chang, Y., You, Y., Moore, P., & Goldsmith, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19625 · Cited by 295 · see citing works
Targeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 277 · see citing works
Ohtani, T., Ishihara, K., Atsumi, T., Nishida, K., Kaneko, Y., Miyata, T., Itoh, S., Narimatsu, M., Maeda, H., Fukada, T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80162-4 · Cited by 284 · see citing works
“…SHP2- and STAT3-mediated signals generated from family cytokines to their receptors activates Janus ki- gp130 in vivo, we generated a series of knockin mouse nases (JAK1, JAK2, and TYK2) (Lutticken et al., 1994; lines, in which the SHP2- and/or STAT3-mediated sig- nals are specifically disrupted.”
BackgroundMultiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Hallek, M. J., Bergsagel, P. L., & Anderson, K. C. (1998) · Blood · doi:10.1182/blood.v91.1.3 · Cited by 747 · see citing works
JAKs, STATs and Src kinases in hematopoiesis
Rane, S. G., & Reddy, E. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205398 · Cited by 241 · see citing works
“…of hematopoietic cells appears to result predominantly in the activation of JAK2, although JAK1 and TYK-2 have also been found to be activated in certain cell systems (Silvennoinen et al., 1993a,b; Quelle et al., 1994; Lutticken et al., 1994; Chaturvedi et al., 1997, 1998; Jaster et al., 1997).”
BackgroundIL-6 signal transduction and its physiological roles: the signal orchestration model
Kamimura, D., Ishihara, K., & Hirano, T. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0012-2 · Cited by 673 · see citing works
“gp130 constitutively associates with JAK1, JAK2, and TYK2 (Lutticken et al. 1994; Narazaki et al. 1994; Stahl et al. 1994).”
BackgroundNovel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family.
Senaldi, G., Varnum, B., Sarmiento, U., Starnes, C., Lile, J., Scully, S., Guo, J., Elliott, G., McNinch, J., Shaklee, C. L., et al. (1999) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.96.20.11458 · Cited by 265 · see citing works
Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction (*)
Kaptein, A., Paillard, V., & Saunders, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.11.5961 · Cited by 264 · see citing works
Qiu, Y., Robinson, D., Pretlow, T., & Kung, H. (1998) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.95.7.3644 · Cited by 258 · see citing works
Chen, R., Chang, M.-C., Su, Y., Tsai, Y.-T., & Kuo, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23013 · Cited by 224 · see citing works
Regulation of autophagy by stress-responsive transcription factors
Pietrocola, F., Izzo, V., Niso‐Santano, M., Vacchelli, E., Galluzzi, L., Maiuri, M. C., & Kroemer, G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.05.008 · Cited by 270 · see citing works
gp130 at the nexus of inflammation, autoimmunity, and cancer
Silver, J. S., & Hunter, C. A. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0410217 · Cited by 252 · see citing works
“Under normal circumstances, the Janus kinases JAK1, JAK2, and tyrosine kinase 2 are constitutively associated with gp130, but receptor engagement leads to their phosphorylation and activation [17, 18].”
BackgroundHBx Protein of Hepatitis B Virus Activates Jak1-STAT Signaling
Lee, Y., & Yun, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25510 · Cited by 233 · see citing works
Stahl, N., & Yancopouloš, G. (1994) · Journal of Neurobiology · doi:10.1002/neu.480251111 · Cited by 254 · see citing works
Characterization of the role of IL‐6 in the progression of prostate cancer
Chung, T., Yu, J.-Q., Spiotto, M., Bartkowski, M., & Simons, J. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990215)38:3 · Cited by 253 · see citing works
Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms
Haga, S., Terui, K., Zhang, H. Q., Enosawa, S., Ogawa, W., Inoue, H., Okuyama, T., Takeda, K., Akira, S., Ogino, T., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17970 · Cited by 237 · see citing works
“Stat3 was first described as a molecule with DNA-binding activity, found in IL-6–stimulated hepatocytes, that was capable of selectively interacting with an enhancer element in the promoter of acute-phase genes known as the acute-phase response element (6, 7).”
BackgroundJAK/STAT signaling by cytokine receptors.
Liu, K. D., Gaffen, S., & Goldsmith, M. A. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80165-9 · Cited by 250 · see citing works
Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
McFarland-Mancini, M. M., Funk, H. M., Paluch, A. M., Zhou, M., Giridhar, P. V., Mercer, C. A., Kozma, S. C., & Drew, A. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901929 · Cited by 249 · see citing works
“The Janus family kinases, JAK1, JAK2, and TYK2, are constitutively associated with the cytoplasmic tail of gp130 and phosphorylate gp130 dimers (6, 7).”
BackgroundLeaman, D. W., Pisharody, S., Flickinger, T., Commane, M., Schlessinger, J., Kerr, I. M., Levy, D., & Stark, G. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.369 · Cited by 249 · see citing works
“For example, interleukin 6, CNTF, and OSM, all of which use a common gp130 receptor subunit, activate multiple JAK proteins which differ depending on the cell line examined (38, 63).”
BackgroundKamiya, S., Owaki, T., Morishima, N., Fukai, F., Mizuguchi, J., & Yoshimoto, T. (2004) · Journal of Immunology · doi:10.4049/jimmunol.173.6.3871 · Cited by 248 · see citing works
STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition
Fukada, T., Ohtani, T., Yoshida, Y., Shirogane, T., Nishida, K., Nakajima, K., Hibi, M., & Hirano, T. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6670 · Cited by 247 · see citing works
Series Introduction: JAK-STAT signaling in human disease
Schindler, C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15644 · Cited by 217 · see citing works
Self-citationMellado, M., Rodríguez-Frade, J., Aragay, A., del Real, G., Martín, A., Vila-Coro, A., Serrano, A., Mayor, F., & Martínez-A, C. (1998) · Journal of Immunology · doi:10.4049/jimmunol.161.2.805 · Cited by 246
“Furthermore, STAT3, but not STAT5, is associated to the CCR2 following MCP-1 activation in accordance with the role assigned to the JAK tyrosine kinases in transducing signals from hemopoietic growth factor receptors (38).”
BackgroundIL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled
Reddy, E. P., Korapati, A. L., Chaturvedi, P., & Rane, S. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203594 · Cited by 224 · see citing works
“…of hematopoietic cells appears to result predominantly in the activation of JAK-2, although JAK-1 and TYK-2 have also been found to be activated in certain cell systems (Silvennoinen et al., 1993; Quelle et al., 1994; Lutticken et al., 1994; Chaturvedi et al., 1997, 1998; Jaster et al., 1997).”
BackgroundInterleukin 6 and liver regeneration
STREETZ, K. L., LUEDDE, T., MANNS, M. P., & TRAUTWEIN, C. (2000) · Gut · doi:10.1136/gut.47.2.309 · Cited by 238 · see citing works
SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130
Lehmann, U., Schmitz, J., Weissenbach, M., Sobota, R. M., Hörtner, M., Friederichs, K., Behrmann, I., Tsiaris, W., Sasaki, A., Schneider-Mergener, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210552200 · Cited by 236 · see citing works
Self-citationHorseman, N., & Yu-Lee, L. (1994) · Endocrine reviews · doi:10.1210/edrv-15-5-627 · Cited by 234 · see citing works
Leukemia Inhibitory Factor–dependent Transcriptional Activation in Embryonic Stem Cells
Bœuf, H., Hauss, C., Graeve, F. D., Baran, N., & Kédinger, C. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.6.1207 · Cited by 226 · see citing works
“Activation of these kinases occurs as a result of LIFinduced dimerization of the receptor components (gp130LIFR b ) and leads to their phosphorylation (22, 31, 34, 52, 53).”
BackgroundInfluentialReilley, M. J., Mccoon, P. E., Cook, C., Lyne, P. D., Kurzrock, R., Kim, Y., Woessner, R. D., Younes, A., Nemunaitis, J. J., Fowler, N. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 268 · see citing works
Germain, D., & Frank, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2491 · Cited by 227 · see citing works
Schumann, R. R., Kirschning, C., Unbehaun, A., Aberle, H. P., Knope, H. P., Lamping, N., Ulevitch, R., & Herrmann, F. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3490 · Cited by 226 · see citing works
“This site is found in all acute-phase promoters, and our data agree with those of other studies, stressing the role of this site for IL-6-mediated gene activation (11, 12, 36).”
BackgroundResultThe Janus protein tyrosine kinase family and its role in cytokine signaling.
Ihle, J. (1995) · Advances in Immunology · doi:10.1016/s0065-2776(08)60582-9 · Cited by 225 · see citing works
STAT3 is constitutively activated in Hodgkin cell lines.
Kube, D., Holtick, U., Vockerodt, M., Ahmadi, T., Haier, B., Behrmann, I., Heinrich, P. C., Diehl, V., & Tesch, H. (2001) · Blood · doi:10.1182/blood.v98.3.762 · Cited by 223 · see citing works
Self-citationProtein Kinase C δ Associates with and Phosphorylates Stat3 in an Interleukin-6-dependent Manner*
Jain, N., Zhang, T., Wei, H.-K., Li, W.-Q., & Cao, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24392 · Cited by 222 · see citing works
Smit, L. S., Meyer, D., Billestrup, N., Norstedt, G., Schwartz, J., & Carter-Su, C. (1996) · Molecular Endocrinology · doi:10.1210/mend.10.5.8732683 · Cited by 217 · see citing works
Oncostatin M and hepatocyte growth factor induce hepatic maturation via distinct signaling pathways
Kamiya, A., Kinoshita, T., & Miyajima, A. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02140-8 · Cited by 213 · see citing works
- Authors
- Lütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., Kishimoto, T., Barbieri, G., Pellegrini, S., Sendtner, M., Heinrich, P. C., & Horn, F.
- Affiliations
- RWTH Aachen University (DE)
- ORCID
- Venue
- Science
- Published
- 1994-01-07
- Volume
- 263
- Issue
- 5143
- Pages
- 89-92
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999028040
- Cited by
- 814
- References
- 0
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 11 · 2023: 5 · 2022: 7 · 2021: 13 · 2020: 10 · 2019: 14 · 2018: 14 · 2017: 17 · 2016: 17 · 2015: 23 · 2014: 15 · 2013: 15 · 2012: 20
- FWCI
- 38.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- JAK1, gp130, IL-6 signaling, cytokine-receptor complex, tyrosine phosphorylation, transcription factor activation, leukemia inhibitory factor, oncostatin M, interleukin-11, ciliary neurotrophic factor, signal transduction
- MeSH terms
- Base Sequence, DNA-Binding Proteins, Humans, Interferon-gamma, Membrane Glycoproteins, Molecular Sequence Data, Phosphorylation, Protein-Tyrosine Kinases, Transcription Factors, Tumor Cells, Cultured, Tyrosine, Signal Transduction, Trans-Activators, Antigens, CD, Interleukin-6, Cytokines, STAT1 Transcription Factor, STAT3 Transcription Factor, Cytokine Receptor gp130, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Janus Kinase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
